Posted by AGORACOM-JC
at 8:00 PM on Sunday, December 20th, 2020
As the name implies, ImagineAR (IP:CSE / IPNFF:OTCQB) is an Augmented Reality Company … but they’re not just any AR company. Imagine enables businesses to create their own mobile phone AR campaigns with no programming or technology experience. Why is that important? Ask Apple CEO Tim Cook who stated
“AR Will play an important role in how we use technology in the future – and promises to be as influential in our society as the smart phone”
For those of you that are just discovering Augmented Reality, “AR” is essentially a technology that lays digital images and graphics over the real world, typically by looking through your cell phone or special glasses. If you think it sounds like a gimmick, it isn’t. AR will create an entire new revenue stream for businesses, organizations and sports teams that will boggle the mind in the next 3 years.
ImagineAR provides small cap investors with an opportunity to participate in the growth of this mega market in the making …. and they they signed the MASSIVE brand contracts in 2020 to prove it:
“Shoppers Drug Mart is thrilled to be the global pioneer in integrating mobile augmented reality with virtual events.” (Karen Bossion, Director Conferences & Events)
We could go on but you get the pont …. and some of the smartest people in sports agree the Company is a best of breed company:
“In my 30 years working in sports and entertainment technology, I have never seen a solution that provides such a high level of interaction & engagement” (Chris Dill)
“The ImagineAR platform is years ahead of every other company today” (WaV Sports)”
“ImagineAR has one of the most amazing mobile technologies I have seen to date” (Gus Frerotte)
“The ImagineAR augmented reality platform is truly a gamechanger for sports organizations and athletes to deliver in-home mobile phone engagement” (WaV Sports)
2020 was a great year and a major turning point for ImagineAR and sets up the Company for an ever far better 2021 … which explains why our latest interview with CEO Alen Paul Silverrstieen is by far the best one of the year.
Posted by AGORACOM-JC
at 8:16 AM on Thursday, December 17th, 2020
Enables the World’s Lowest-Cost and Smallest 100G CWDM4 Optical Engine
Completed and tested its high-speed Directly Modulated Laser (DML) designs using a distributed feedback (DFB) structure and successfully “flip-chipped” these lasers onto the Company’s Optical Interposer platform, which also incorporates several other industry-first accomplishments.
flip-chip assembly technique enables a true single-chip, fully integrated Optical Engine to be produced at wafer-scale, resulting in the lowest-cost, smallest-size 100G CWDM4 Optical Engine with a form factor of 9mm x 6mm, while including banks of four lasers, four monitor photodiodes, four high speed photodiodes, a multiplexer, demultiplexer, taps for power monitoring and features supporting a self-aligned fiber attach unit.
TORONTO, Dec. 17, 2020 — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF) the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced today that it has completed and tested its high-speed Directly Modulated Laser (DML) designs using a distributed feedback (DFB) structure and successfully “flip-chipped” these lasers onto the Company’s Optical Interposer platform, which also incorporates several other industry-first accomplishments.
The flip-chip assembly technique enables a true single-chip, fully integrated Optical Engine to be produced at wafer-scale, resulting in the lowest-cost, smallest-size 100G CWDM4 Optical Engine with a form factor of 9mm x 6mm, while including banks of four lasers, four monitor photodiodes, four high speed photodiodes, a multiplexer, demultiplexer, taps for power monitoring and features supporting a self-aligned fiber attach unit.
“Without being able to flip-chip the lasers, we would be unable to assemble Optical Engines at wafer-scale, which is the single most important driver of cost. Wafer-scale processing enables the production of high unit volumes at low incremental costs, ultimately allowing us to reduce the cost of building photonics devices by 25% to 40% compared to conventional approaches,” stated Suresh Venkatesan, Chairman and CEO of POET. “Following our successful demonstration of this flip-chip assembly process, POET can now readily incorporate these lasers and other active devices into derivative optical engine configurations, supporting data communications applications such as 200G CWDM4, 100G CWDM6, and 100G LR4, telecom applications such as 5G, as well as other applications that could benefit from the small size and low cost of our platform technology.”
Four DML lasers are commonly used in 100G transceiver applications, a key initial target market for POET’s Optical Interposer, enabling high speed optical communication in the 2 to 10 km range. Operating at speeds of 25 gigabits per second (GPS), POET’s family of four DML lasers of different wavelengths are the first known commercial 25G DFB-type DML lasers to utilize a flip-chip process to passively align and bond to electronic and optical circuitry on the interposer platform, while maintaining optimal performance. Given the estimated total available market (TAM) for 100G transceivers of approximately $2.5 billion, POET believes that its recently formed JV company, SuperPhotonics Xiamen, can achieve annual revenue of over $100 million within this single market segment in the 2024-25 time frame.
Flip-chip assembly of electronic devices on circuit boards, MEMS (Microelectromechanical Systems) and other devices is an advanced manufacturing process for achieving electrical interconnect (often referred to as 2-D, 2.5-D and 3-D) in semiconductor architectures. To achieve the benefits of the planar architecture of POET’s Optical Interposer that facilitates wafer-scale processing, flip-chipping of lasers was an important development milestone, requiring POET to demonstrate that it could simultaneously optimize the RF (radio frequency) performance of the flip-chipped DML laser on interposer while preserving a low RIN (relative intensity noise) measurement both before and after assembly. RF performance relates to the quality and power of the electrical signals, while RIN is a measure of stability of the lasers that are assembled on the Interposer.
“Beyond The Press Release”
POET Technologies goes “Beyond The Press Release” to discuss today’s news. Shareholders and other interested parties are encouraged to check back on this link before market open on the morning of Tuesday December 22, 2020.
About POET Technologies Inc. POET Technologies is a design and development company offering integration solutions based on the POET Optical Interposer™ a novel platform that allows the seamless integration of electronic and photonic devices into a single multi-chip module using advanced wafer-level semiconductor manufacturing techniques and packaging methods. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, burn-in and testing methods employed in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to any device or system that integrates electronics and photonics, including some of the highest growth areas of computing, such as Artificial Intelligence (AI), the Internet of Things (IoT), autonomous vehicles and high-speed networking for cloud service providers and data centers. POET is headquartered in Toronto, with operations in Allentown, PA and Singapore. More information may be obtained at www.poet-technologies.com .
Shareholder Contact for POET: Shelton Group Brett L. Perry [email protected]
Company Contact for POET: Thomas R. Mika, EVP & CFO [email protected]
This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements include the Company’s expectations with respect to the success of the Company’s product development efforts, the performance of its products, the expected results of its operations, meeting revenue targets, and the expectation of continued success in the financing efforts, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products.
Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding the success and timing for completion of its development efforts, financing activities, future growth, recruitment of personnel, opening of offices, the form and potential of its planned joint venture, plans for and completion of projects by the Company’s third-party consultants, contractors and partners, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, the failure of its products to meet performance requirements, operational risks in the completion of the Company’s anticipated projects, a delay or abandonment of its planned joint venture, delays in recruitment for its newly opened operations or changes in plans with respect to the development of the Company’s anticipated projects by third-parties, risks affecting the Company’s ability to execute projects, the ability of the Company to generate sales for its products, the ability to attract key personnel, and the ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 – Fax: 416-322-5075
Posted by AGORACOM-JC
at 4:31 PM on Wednesday, December 16th, 2020
Kontrol Energy Corp. ( CSE: KNR ) ( OTCQB: KNRLF ) ( FSE: 1K8 ) will be hosting a webinar presentation for investors, analysts and media for its Covid-19 detection technology (“BioCloud analyzer” or “BioCloud”). The purpose of the presentation is to provide an operating demonstration and take questions from the audience.
“Following the filing of our patent applications we are excited to demonstrate how the BioCloud technology operates and share that with the public,” says Paul Ghezzi , CEO Kontrol. “We will be providing a demonstration of BioCloud and access to the inner workings of the technology.”
Title: Kontrol to host BioCloud technology presentation for investors, analysts and media
Event date: Thursday, Dec. 17, 2020, at 4:30 p.m. Eastern Time
Presentation type: audio with presenter controlled slides and teleconference
Posted by AGORACOM
at 11:04 AM on Wednesday, December 16th, 2020
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
Purchasers of Marijuana Pay About 10 Percent in State Taxes on Retail Buys
The sale of cannabis in California went legal in 2016, and retailers were able to open their doors two years later. Along with the legal retail sale of cannabis came two new taxes — a cultivation tax on all harvests and an excise tax on the purchase of weed and products made with it; the usual sales taxes, both state and local, also applied. They add up, and in the third quarter of 2020, California’s total cannabis tax revenue was $306.7 million. Of that amount, the state gained sales and excise tax on $11 million worth of retail cannabis sold in cities in Santa Barbara County.
For $30 worth of cannabis flower, or buds, the taxes can raise the consumer’s payment to $41.77, the state Tax and Fee Administration (CDTFA) calculated. That includes a 15 percent excise tax and the state’s 8.5 percent sales tax. The CDTFA also added a 10 percent cannabis business tax, which is charged by most California jurisdictions, although Santa Barbara County’s cities’ rate is 5-6 percent. The cultivation tax is paid by weight when the farmer sells to a distributor.
The breakdown of the $306 million in taxes are excise tax of $159.8 million, cultivation tax of $41 million, and sales tax of $105.9 million. For the previous year’s July to September, the cannabis taxes to the state were $170.8 million.
The previous quarter, or April through June, generated $260 million for the state, and the first quarter of January to March generated close to $206 million. Santa Barbara County’s retail cannabis sales saw a similar move upward from the first to second quarter, the Tax and Fee Administration reported. January to March sales were $9 million, and April to May sales were $16.7 million. Many speculate the increase is due to the shutdown.
Santa Barbara County has yet to permit any retail cannabis stores and is in the process of determining where eight will go in the county’s unincorporated areas. If the $11 million in sales would have occurred in county areas, the income would have been about $441,000 with the county’s 4 percent retail cannabis tax, said Jeff Frapwell of the County Executive Office.
Correction: Santa Barbara County plans eight retail cannabis stores, not six; and this story has been updated to reflect local business tax amounts.
Posted by AGORACOM-JC
at 7:22 AM on Wednesday, December 16th, 2020
Company’s board of directors has authorized management to review the process to graduate the Company from the CSE to the TSX
If the Company is successful in uplisting to the TSX, Kontrol intends to, as soon as practical, begin the process of filing a Form F-1 Registration Statement with the Securities and Exchange Commission of the United States, which will enable Kontrol to apply to be listed on the NASDAQ
TORONTO, ON / December 16, 2020 / Kontrol Energy Corp.(CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that it has completed its previously announced debenture exchange (see press release dated June 9, 2020 and November 2, 2020) by private placement. The 2020 Debenture holders exchanged a total of $3,650,000 for 2022 Debentures and new proceeds of $871,000 were raised. The remaining 2020 Debenture balance of $2,061,000 was redeemed in cash by the Company. Each unit is comprised of one $1,000 8% unsecured debenture (and non-convertible) of the Company maturing on October 31, 2022 and 10 common shares.
Paul Ghezzi, CEO of Kontrol, commented:
“With the exchange of the 2020 Debentures we have improved the balance sheet and the Company’s net equity position. As we continue to execute on our business plan, we believe this is an opportune time to begin the graduation process to the senior North American exchanges for an uplisting in 2021.”
Name Change
Further to the passing of a resolution of shareholders at its most recent general and special meeting of shareholders, the Company intends to proceed with a corporate name change to “Kontrol Technologies Corp.”, which is anticipated to be completed prior to December 31, 2020.
Uplisting to TSX, NASDAQ
The Company’s board of directors has authorized management to review the process to graduate the Company from the CSE to the TSX. If the Company is successful in uplisting to the TSX, Kontrol intends to, as soon as practical, begin the process of filing a Form F-1 Registration Statement with the Securities and Exchange Commission of the United States (the “SEC“), which will enable Kontrol to apply to be listed on the NASDAQ.
Completion of any uplisting is subject to meeting certain conditions, as well as the approval of the TSX. There is no assurance that the TSX will approve the listing application or that Kontrol will complete the uplisting as contemplated. There is no assurance that either the SEC or NASDAQ will approve the Company’s respective applications or that Kontrol will complete the listing to the NASDAQ as proposed.
About Kontrol Energy
Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp. 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 11:38 AM on Tuesday, December 15th, 2020
Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.
3 Fully Operating Divisions For Investor Diversification
Innocan has 3 fully operating divisions to address the market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.
PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.
Global Manufacturing / Distribution Agreements
Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
iAmHealth Distribution UG (Distribution – Germany)
Completed Trademark Registration in the EU, UK and Switzerland
Completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland.
These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.
Superior Management Team
In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself. The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:
Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
Together they have built one of the most formidable teams in the small cap cannabis world
Posted by AGORACOM-JC
at 7:26 AM on Tuesday, December 15th, 2020
Entered into a distribution agreement with Grande West, a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, to offer BioCloudTM technology to the Vicinity line of buses.
Under the terms of the non-exclusive distribution agreement, Grande West will offer the BioCloud solution as an option in its Vicinity LightningTM, Vicinity LT and Vicinity heavy duty bus specifications.
Grande West’s existing customers will be notified of the option to retrofit the BioCloud devices into existing fleets across Canada.
TORONTO, ON / December 15, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has entered into a distribution agreement with Grande West, a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, to offer BioCloudTM technology to the Vicinity line of buses.
“We are pleased to enter into this agreement with Grande West as we continue to target the important sector of ground transportation with an established and successful bus OEM. We are excited to be working with another disruptive Canadian company, focusing on a transit solution that will make buses safer and reduce risk of potential viral spread for the riders,” stated Paul Ghezzi, CEO Kontrol Energy. “We anticipate that this additional partnership will add another channel for incremental sales as the need for safe detection of airborne viruses in public spaces grows.”
Under the terms of the non-exclusive distribution agreement, Grande West will offer the BioCloud solution as an option in its Vicinity LightningTM, Vicinity LT and Vicinity heavy duty bus specifications. Grande West’s existing customers will be notified of the option to retrofit the BioCloud devices into existing fleets across Canada. United States customers will be serviced by working with Kontrol Energy’s exclusive distributor, United Safety and Survivability Corporation. Pricing will not be disclosed for industry competitive purposes.
William Trainer, President & CEO of Grande West stated, “Grande West is proud to be partnering with Kontrol in working towards making our Vicinity buses safer for all of our end users. The Company is expanding its product lines into Electric Vehicles and lighter duty models and ramping up its U.S. sales and expects significant growth in the coming years. We will do everything we can to offer the safest and most effective transit solutions to our customers.”
As an initial step, Grande West is immediately ordering two of BioCloud units for its offices and operations headquarters in Aldergrove to improve the safety considerations of its employees.
About BioCloudTM
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com
About Grande West Transportation Group
Grande West Transportation is a Canadian company that designs and engineers mid-size multi-purpose transit vehicles for public and commercial enterprises. Grande West utilizes world-class manufacturing partners to produce the Purpose-Built VicinityTM medium and heavy-duty buses available in electric, CNG, gas and clean diesel drive systems. The Vicinity LightningTM EV with an electric propulsion drive system is available for 2021 deliveries.
The Company has been successful in supplying Canadian municipal transportation agencies and private operators with new buses. Grande West is compliant to Buy America certification, and with a strong distribution chain in the U.S., is actively pursuing opportunities in public and private transit fleet operations that would benefit from Grande West’s vehicles.
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp. 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloudTM (“BioCloud”) are subject to the risk that the Kontrol BioCloud may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 4:19 PM on Monday, December 14th, 2020
“It basically obliterates transmission of this virus”
This was the testimony of Pierre Kory, M.D., Associate Professor of Medicine at St. Luke’s Aurora Medical Center, delivers passionate testimony during the Senate Homeland Security and Governmental Affairs Committee hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution, Part II.”
We interviewed Leigh Hughes, newly appointed Advisor to MVMD who will be supporting the Company in the areas of M&A, corporate finance and pharmaceutical licensing, to provide us with further insight as to why the testimony of Dr. Kory is so relevant to MVMD … and why Dr. Kory actually called MVMD last week to discuss the Company’s involvement with Ivermectin.
Mountain Valley MD has traded over 50,000,000 shares in the last 3 trading days, so there is a clear need for information amongst retail investors.
Posted by AGORACOM-JC
at 12:09 PM on Monday, December 14th, 2020
Else Nutrition Holdings Inc. (BABY: TSXV) (BABYF: OTCQX) (0YF: FSE) is the award winning, plant-based nutrition company for small cap investors. The shift towards plant-based alternatives has opened the food market to new players, and created an opportunity for fast growth in a rapidly expanding space. Else has fully grasped at this opportunity as seen below.
Highlights include:
$CAD 30 Million In Cash
Launched 1st Commercial Product Into US Market
Backed By A $2.7 Billion Dollar Global Nutrition Company;
MOU For International Distribution Of Products
“Best Health” Award At Global Food Innovation Summit In Milan;
Awarded Patents In 22 Countries, 44 Countries Pending;
Executives & Advisors From Globally Renowned Companies & Institutions
Distribution agreement with one of the largest and most well regarded national fresh, organic and specialty food distributors in North America
Received key Clean Label Certifications for Toddler Nutrition Product
Received Key USDA Organic Certification
Else Nutrition’s Complete Nutrition for Toddlers ranked Top-Selling Product on Amazon’s Hot New Releases in Baby and Toddler Formula Category
